nootropil 800 mg apvalkotās tabletes
ucb pharma sa, belgium - piracetāms - apvalkotā tablete - 800 mg
nootropil 800 mg apvalkotās tabletes
ucb pharma sa, belgium - piracetāms - apvalkotā tablete - 800 mg
briviact (in italy: nubriveo)
ucb pharma sa - brivaracetāms - epilepsija - antiepileptics, - briviact ir norādīts kā adjunctive terapiju daļēju sākums lēkmju ar vai bez sekundāras vispārināšanas pieaugušo un pusaudžu pacientiem no 16 gadu vecuma ar epilepsiju.
vimpat
ucb pharma sa - lacosamide - epilepsija - antiepileptics, - vimpat ir indicēts kā monoterapija un papildu terapija daļējas lēkmes lēkmju ar sekundāro ģeneralizāciju vai bez tās ārstēšanai pieaugušajiem, pusaudžiem un bērniem no 4 gadu vecuma ar epilepsiju.
xyrem
ucb pharma ltd - sodium oxybate - cataplexy; narcolepsy - other nervous system drugs - narkolepsijas ārstēšana ar katapleksiju pieaugušiem pacientiem.
evenity
ucb pharma s.a. - romosozumab - osteoporoze - zāles kaulu slimību ārstēšanai - evenity ir norādīts ārstēšana smagas osteoporozes ārstēšanai sievietēm pēcmenopauzes periodā ir augsts risks lūzums.
bimzelx
ucb pharma s.a. - bimekizumab - psoriāze - imūnsupresanti - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
cirrus 5 mg/120 mg ilgstošās darbības tabletes
ucb pharma oy finland, finland - cetirizini dihydrochloridum, pseudoephedrini hydrochloridum - ilgstošās darbības tablete - 5 mg/120 mg
vasaprostan 20 mikrogrami pulveris infūziju šķīduma pagatavošanai
ucb pharma gmbh, germany - alprostadils - pulveris infūziju šķīduma pagatavošanai - 20 μg